Lexaria Bioscience Corp 8-K Report: Key Financial Insights for December 2024

Based on the provided XML section of the financial report, here are the key pieces of information extracted:

1. Entity Information:

• Company Name: Lexaria Bioscience Corp
• CIK (Central Index Key): 0001348362
• SEC File Number: 000-39874
• Tax Identification Number: 20-2000871
• Address: 740 McCurdy Road, Kelowna, BC, Canada, V1X 2P7
• Phone Number: 250-765-6424

2. Report Type:

• Filing Type: 8-K (Current Report)
• Date of Filing: December 16, 2024

3. Stock Information:

• Common Stock: Par value of $0.001 per share
• Warrants: Associated with the purchase of common stock
• Ticker Symbols:
• • Common Stock: LEXX
  • Warrants: LEXXW
• Exchange: NASDAQ

4. Reporting Period:

• Start Date: December 16, 2024
• End Date: December 16, 2024

5. Financial Metrics:

• Currency: USD (United States Dollar)
• Measure Units:
• • Shares (for stock measurements)
  • USD per share (for valuations)

6. Dimensions:

• The financial data is segmented into different classes of stock, specifically:
• • Common Stocks
  • Warrants

Insights:

• The report indicates that Lexaria Bioscience Corp is actively engaging in financial activities involving common stock and warrants, which could be indicative of efforts to raise capital or manage equity structure.
• The filing of an 8-K suggests that the company is disclosing significant events or changes that might be of interest to stakeholders, which is crucial for transparency and regulatory compliance.
• The specific mention of stock and warrants might imply potential future financing activities or changes in capital strategy that investors should monitor.

Overall, this section of the financial report provides an overview of the company's identity, financial instruments, and current reporting status, which are critical for investors and analysts following Lexaria Bioscience Corp.